Macrolide Resistance in M. pneumoniae, Israel | CDC EID

EID Journal Home > Volume 17, Number 6–June 2011

EID Journal Home > Volume 17, Number 6–June 2011

Volume 17, Number 6–June 2011
Dispatch
Macrolide Resistance in Mycoplasma pneumoniae, Israel, 2010
Diana Averbuch,1 Carlos Hidalgo-Grass,1 Allon E. Moses, Dan Engelhard, and Ran Nir-Paz
–Hebrew University Medical Center, Jerusalem, Israel

Suggested citation for this article

Abstract
Macrolide resistance in Mycoplasma pneumoniae is often found in Asia but is rare elsewhere. We report the emergence of macrolide-resistant M. pneumoniae in Israel and the in vivo evolution of such resistance during the treatment of a 6-year-old boy with pneumonia.

Mycoplasma pneumoniae is a leading respiratory pathogen in both pediatric (1,2) and adult (1,3) populations. Macrolides are considered the first line of therapy and are almost the only treatment for children. In recent years, alarming rates of M. pneumoniae with macrolide resistance (<90%) have occurred in eastern Asia, including the People's Republic of China, Japan, and Korea (2,4–7). This was initially reported in children; however, a surge of resistance in adults was recently reported (2,4,7). Macrolide-resistant M. pneumoniae has also been suggested to be associated with a longer course of disease (2,4). In the Western Hemisphere, lower rates of macrolide resistance have been reported (<10%), however, several epidemics with notable complications have occurred (8–11). We report the detection of macrolide resistance in M. pneumoniae in Israel. full-text: Macrolide Resistance in M. pneumoniae, Israel | CDC EID


Suggested Citation for this Article
Averbuch D, Hildalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis [serial on the Internet]. 2011 Jun [date cited]. http://www.cdc.gov/EID/content/17/6/1079.htm

DOI: 10.3201/eid1706.101558



1These authors contributed equally to this article.


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Ran Nir-Paz, Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem 91120, Israel; email: ran.nirpaz@gmail.com